ESTRO 2021 Abstract Book

S398

ESTRO 2021

Conclusion G2+ acute adverse events are common with overall rates similar across concomitant therapy-fractionation schedules. The toxicity profile varied by type of concurrent treatment; for both fractionation schedules, GI toxicity rate appear higher in patients receiving gemcitabine.

Proffered papers: Proffered papers 31: Head and neck

OC-0514 Long-term follow up of a RCT of Accelerated Radiotherapy for early Glottic Cancer (JCOG 0701A3) T. Kodaira 1 , Y. Kagami 2 , R. Machida 3 , N. Shikama 4 , Y. Ito 2 , S. Ishikura 5 , Y. Saito 6 , Y. Matsumoto 7 , K. Konishi 8 , N. Murakami 9 , T. Akimoto 10 , Y. Fukushima 11 , T. Toshiyasu 12 , K. Nakagawa 13 , Y. Nagata 14 , H. Ogawa 15 , T. Uno 16 , Y. Hamamoto 17 , Y. Nishimura 18 1 Aichi Cancer Center, Department of Radiation Oncology, Nagoya, Japan; 2 Showa University School of Medicine, Department of Radiation Oncology, Tokyo, Japan; 3 National Cancer Center, Japan Clinical Oncology Group Data Center, Tokyo, Japan; 4 Jyuntendo University, Department of Radiation Oncology, Tokyo, Japan; 5 Nagoya City University Graduate School of Medical Sciences, Department of Radiology, Nagoya, Japan; 6 Saitama Cancer Center Hospital, Department of Radiation Oncology, Saitama, Japan; 7 Niigata Cancer Center Hospital, Department of Radiation Oncology, Niigata, Japan; 8 Osaka International Cancer Institute, Department of Radiation Oncology, Osaka, Japan; 9 National Cancer Center Hospital , Department of Radiation Oncology, Tokyo, Japan; 10 National Cancer Center Hospital East, Department of Radiation Oncology, Kashiwa, Japan; 11 Sapporo Medical University, Department of Radiology, Sapporo, Japan; 12 The Cancer Institute Hospital of JFCR, Department of Radiation Oncology, Tokyo, Japan; 13 Tokyo University, Department of Radiology, Tokyo, Japan; 14 Hiroshima University, Department of Radiation Oncology, Hiroshima , Japan; 15 Shizuoka Cancer Center, Division of Radiation Oncology, Shizuoka, Japan; 16 Chiba University Hospital, Department of Radiology, Chiba , Japan; 17 Shikoku Cancer Center, Department of Radiation Oncology, Matsuyama, Japan; 18 Kindai University Faculty of Medicine, Department of Radiation Oncology, Osaka- Sayama, Japan Purpose or Objective JCOG0701A3 is designed to assess results with long-term follow up of JCOG0701, as of a randomized controlled trial comparing efficacy of accelerated fractionation with 2.4 Gy/fraction (Ax group) to that of standard fractionation with 2 Gy/fraction (SF group) for glottic cancer (GC). Materials and Methods GC of T1-2N0M0, were treated with 66/70 Gy for T1/T2 in SF group, while 60/64.8 Gy in Ax group in JCOG0701. The primary analysis underwent on February, 2016, and reported in 2018. Present analysis was designed to add additional results with longer follow up progression-free survival (PFS), overall survival (OS), larynx progression-free survival (LPFS), and late adverse events adding central nervous system ischemia (CNSI). The analysis was conducted in June 2020. Results There were 370 patients randomized to SF and Ax group with 184 and 186 patients, respectively. Patients were adjusted for T category and institute at randomization. All patients included 356 males/14 females, and 341/29 patients with PS 0/1. Median age was 68 (range, 35−80). Among SF group, 138/46 patients had T1/T2 disease, while 140/42 had T1/T2 in Ax group. In this ancillary analysis, the median follow-up period of the entire /those without disease progression was 7.1/8.0 years (range, 0.1−12.4/0.1-12.4). At last follow-up, 45/260 patients were alive with/without disease progression and 65 patients died. As of SF/Ax group, 8/9 patients died of the primary disease, 23/17 of other cause, 1/1 of treatment related death and 1/5 of unknown reasons, respectively. The 7-years cumulative incidences of local failure at last follow up of SF/Ax group were 18.4%/10.9%, and those of regional or distant failure and those of death were 2.2%/6.7%, and 6.1%/7.5%, respectively. The 5 and 7-years PFS of SF/Ax group was 76.2%/78.2% and 72.7%/74.8%, and the 5 and 7-years OS of SF/Ax group was 92.7%/89.6% and 90.8%/86.5%, LPFS of both group was 77.8%/80.9 and 74.4%/77.6%, respectively. As for late toxicity (≥91 days), 14.3%/7.6% of ≥grade 2 and 3%/1.6% of ≥grade 3 observed in SF/Ax group.